Oncolytics Biotech Inc. (ONCY) Q1 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Oncolytics Biotech's first quarter 2024 conference call. All participants are now in listen-only mode. There will be a question and answer session at the end of this call. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to John Patton, Director of Investor Relations and Communication. Please go ahead. Thank you, Operator, and good afternoon, everyone. Earlier today, OnClinic's issued a press release providing recent operational highlights and financial results for the first quarter of 2024. A replay of today's call will be available on the event section of the OnClinic's website approximately two hours after its completion. After remarks from company management, we will open the call for Q&A. As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of Pellegrino Rep. Including statements regarding the company's mission, the company's belief as an essential and mechanism of action of Pellery Rep as a cancer therapeutic, our belief that we are positioned to begin registrational track studies in breast and pancreatic cancer, and our strategies and upcoming milestones in connection therewith. Our critical objectives for 2024, the anticipated timing and the release of additional data, the company's belief that it has sufficient cash to achieve these milestones, and other statements related to anticipated developments in the company's business. These statements are based on management's current expectations and beliefs and are subject to a number of factors which involve known and unnoticed delays, uncertainties, and other factors not under the company'...